Blade Air Mobility Inc

Blade Air Mobility, Inc. (NASDAQ: BLDE) provides air transportation and logistics for hospitals across the United States. The Company transports human organs for transplant, and for passengers, with helicopter and fixed wing services primarily in the Northeast United States and Southern Europe. It operates in three key product lines across its Passenger and Medical segments. 

Recent Business and Financial Updates

• Blade Air Mobility Reports Improved Financial Results for Q4 and Full Year 2024: Blade Air Mobility, Inc. (Nasdaq: BLDE), headquartered in New York, announced its financial outcomes for the fourth quarter and full year ended December 31, 2024, demonstrating significant progress. The Company reported a full-year net loss of USD27.3 million, a USD28.8 million from the prior year, while Adjusted EBITDA advanced by USD17.8 million to USD1.2 million, marking its first full year of profitability on this metric. In the fourth quarter, revenue rose by 14.5% to USD54.4 million compared to USD47.5 million in the previous year, with an adjusted increase of 22.1% excluding the Canadian market, which the Company exited in August 2024. The net loss for Q4 improved by USD24.1 million to USD9.8 million, and Adjusted EBITDA improved by USD4.9 million to a loss of USD0.4 million, reflecting robust operational enhancements.
• Strong Performance Across Passenger and Medical Segments: The Passenger Segment achieved an Adjusted EBITDA of USD3.6 million in 2024, an impressive USD8.6 million increase from the prior year, driven by margin improvements in Short Distance and Jet & Other Passenger services, bolstered by the exit from the Canadian market. Fourth-quarter revenue growth included a 17.7% rise in Short Distance revenue (excluding Canada) to USD9.1 million and an 84.7% surge in Jet and Other revenue to USD8.8 million, fueled by higher flight volumes. The Medical Segment reported a remarkable 119.6% year-over-year improvement in Adjusted EBITDA to USD5.5 million in Q4, supported by a 13.7% revenue increase to USD36.4 million, attributed to higher trip volumes and strategic fleet positioning that reduced repositioning costs and enhanced responsiveness.
• Operational Efficiency and Strategic Investments: Blade’s financial strategy yielded notable efficiencies, with Flight Profit increasing by 39.7% to USD12.6 million in Q4 and Flight Margin improving to 23.2% from 19.0%, reflecting effective capacity management and aircraft investments. The Medical Segment’s owned fleet grew to nine aircraft by December 2024, with a tenth added in February 2025, expected to account for approximately one-third of flight hours in 2025, complemented by third-party aircraft. The Company ended 2024 with USD127.1 million in cash and short-term investments, supporting its operational scale. Capital expenditures of USD5.0 million in Q4, primarily for aircraft purchases, contributed to a Free Cash Flow improvement to USD3.6 million before aircraft acquisitions, underscoring Blade’s focus on sustainable growth.
• Business Highlights and Market Expansion Initiatives: Blade enhanced its market presence with key operational updates, including an alliance with Skyports Infrastructure to launch a pilot program in April 2025, expanding its by-the-seat helicopter transfer service between Downtown Manhattan Heliport and John F. Kennedy International Airport. The Company’s organ placement service, TOPS, concluded the year with six contracted customers and a robust sales pipeline, while the introduction of a new mobile app in March 2025 improved customer experience with features like easy booking and flexible payments. The European restructuring yielded encouraging early results, with strong revenue growth and profitability gains during the winter ski season, positioning Blade for continued expansion in urban air mobility and medical transport services.
• Leadership Perspective and 2025 Financial Outlook: Rob Wiesenthal, Blade’s Chief Executive Officer, highlighted the achievement of full-year Adjusted EBITDA profitability in 2024, driven by significant revenue growth and margin expansion across both segments, setting the stage for multi-year compounding growth in Free Cash Flow and Adjusted EBITDA. Will Heyburn, Chief Financial Officer, emphasized the benefits of economies of scale from aircraft investments and capacity agreements, noting the Medical Segment’s attainment of Adjusted EBITDA margins above the 15% near-term target in Q4, earlier than anticipated. Melissa Tomkiel, President, underscored the competitive edge gained from aircraft ownership, exemplified by new transplant center partnerships in April 2025. Blade reaffirmed its 2025 guidance, projecting revenue of USD245-265 million and double-digit millions in Adjusted EBITDA, signaling confidence in its strategic trajectory.
• Commitment to Sustainable Growth and Innovation: Blade’s progress in 2024 reflects its commitment to leveraging operational efficiencies and strategic investments to transition from helicopter to electric vertical takeoff and landing (eVTOL) services, de-risking its future growth path. The Company’s focus on cost efficiencies in the Passenger business, particularly through services like Blade Airport, which saw high-teens revenue growth in Q4, aligns with its vision to lead in urban air mobility. While forward-looking Adjusted EBITDA guidance remains unreconciled due to variable costs, Blade’s solid financial foundation and innovative service offers position it to navigate market challenges and capitalize on emerging opportunities in the aviation sector.

Technical Observation (on the daily chart):

The 14-day Relative Strength Index (RSI) is currently at 44.68, currently upward trending, with the expectations of consolidation or upward momentum if the USD 2.80-USD 3.00 resistance is broken on the upside. In addition, the current price is below both the 50-day Simple Moving Averages (SMAs) and 200-day SMA, which may work as medium to long term resistance levels.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘WATCH’ rating has been given Blade Air Mobility, Inc. (NASDAQ: BLDE) at the closing price of USD2.68, as of April 24, 2025. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is April 24, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.